非酒精性脂肪性肝炎治疗药物——resmetirom

A therapeutic drug of non-alcoholic steatohepatitis:resmetirom

非酒精性脂肪性肝炎(NASH)发病机制极为复杂,目前尚无标准的治疗方法。resmetirom是一种口服小分子肝脏靶向、选择性甲状腺激素受体β激动剂,其在NASH治疗领域为首个达到Ⅲ期临床试验主要终点的药物,且安全性和耐受性良好,有望成为第1个FDA批准用于治疗NASH的药物。本文对resmetirom的基本信息、作用机制及临床研究等进行综述。

The pathogenesis of non-alcoholic steatohepatitis(NASH)is extremely complex and there is no current standard therapy.Resmetirom is an orally administered small molecule that targets the liver and is a selective thyroid hormone receptorβagonist.It is the first drug in the field of NASH treatment to reach the primary endpoint in phaseⅢclinical trials and has good safety and tolerability profiles,which makes it a hopeful candidate to be the first FDA-approved drug for NASH treatment.This article provides a comprehensive review of resmetirom's basic information,mechanism of action and the findings from clinical trials.